Paclitaxel-eluting stents

John Cosgrave; Corbett Simon; Rade Babic; Antonio Colombo

doi:10.2217/14796678.2.2.229

Paclitaxel-eluting stents

John Cosgrave, Corbett Simon, Rade Babic, Antonio Colombo

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells. Many devices and pharmaceutical agents have been unsuccessful in preventing this problem. Paclitaxel is an antiproliferative drug that has been extensively studied for the prevention of restenosis. This article will review the trial results of the currently available stent platforms and discuss some of the ongoing studies and future directions for the development of new paclitaxel-eluting stents.

Original language	English
Pages (from-to)	229-239
Number of pages	11
Journal	Future Cardiology
Volume	2
Issue number	2
DOIs	https://doi.org/10.2217/14796678.2.2.229
Publication status	Published - Feb 2006

Keywords

Major adverse cardiac events
Paclitaxel-eluting stent
Restenosis
Revascularization

ASJC Scopus subject areas

Molecular Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.2217/14796678.2.2.229

Fingerprint Dive into the research topics of 'Paclitaxel-eluting stents'. Together they form a unique fingerprint.

Cite this

@article{62a92a5b8ba54cd5b6fe9581c6a01a23,

title = "Paclitaxel-eluting stents",

abstract = "Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells. Many devices and pharmaceutical agents have been unsuccessful in preventing this problem. Paclitaxel is an antiproliferative drug that has been extensively studied for the prevention of restenosis. This article will review the trial results of the currently available stent platforms and discuss some of the ongoing studies and future directions for the development of new paclitaxel-eluting stents.",

keywords = "Major adverse cardiac events, Paclitaxel-eluting stent, Restenosis, Revascularization",

author = "John Cosgrave and Corbett Simon and Rade Babic and Antonio Colombo",

year = "2006",

month = feb,

doi = "10.2217/14796678.2.2.229",

language = "English",

volume = "2",

pages = "229--239",

journal = "Future Cardiology",

issn = "1479-6678",

publisher = "Future Medicine Ltd.",

number = "2",

}

TY - JOUR

T1 - Paclitaxel-eluting stents

AU - Cosgrave, John

AU - Simon, Corbett

AU - Babic, Rade

AU - Colombo, Antonio

PY - 2006/2

Y1 - 2006/2

N2 - Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells. Many devices and pharmaceutical agents have been unsuccessful in preventing this problem. Paclitaxel is an antiproliferative drug that has been extensively studied for the prevention of restenosis. This article will review the trial results of the currently available stent platforms and discuss some of the ongoing studies and future directions for the development of new paclitaxel-eluting stents.

AB - Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells. Many devices and pharmaceutical agents have been unsuccessful in preventing this problem. Paclitaxel is an antiproliferative drug that has been extensively studied for the prevention of restenosis. This article will review the trial results of the currently available stent platforms and discuss some of the ongoing studies and future directions for the development of new paclitaxel-eluting stents.

KW - Major adverse cardiac events

KW - Paclitaxel-eluting stent

KW - Restenosis

KW - Revascularization

UR - http://www.scopus.com/inward/record.url?scp=33646597258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646597258&partnerID=8YFLogxK

U2 - 10.2217/14796678.2.2.229

DO - 10.2217/14796678.2.2.229

M3 - Article

C2 - 19804079

AN - SCOPUS:33646597258

VL - 2

SP - 229

EP - 239

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 2

ER -

Paclitaxel-eluting stents

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this